Routine use of mupirocin at the peritoneal catheter exit site and mupirocin resistance: Still low after 7 years

Nephrology Dialysis Transplantation

Volumn 19, Issue 12, 2004, Pages 3140-3143

  Lobbedez, Thierry ^a   Gardam, Michael ^a   Dedier, Helen ^a   Burdzy, Dorothy ^a   Chu, Maggie ^a   Izatt, Sharon ^a   Bargman, Joanne M ^a   Jassal, Sarbjit V ^a   Vas, Stephen ^a   Brunton, James ^a   Oreopoulos, Dimitrios G ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Catheter exit site; Mupirocin; Peritoneal dialysis; Resistance; Staphylococcus aureus

Indexed keywords

COTRIMOXAZOLE; MACROLIDE; METICILLIN; OXACILLIN; PSEUDOMONIC ACID; RIFAMPICIN; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; AXILLA; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; CULTURE MEDIUM; DISEASE CARRIER; FEMALE; HEALTH CARE FACILITY; HUMAN; INGUINAL REGION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; NOSE SMEAR; OUTPATIENT DEPARTMENT; PATIENT SELECTION; PERITONEAL CATHETER; PERITONEAL DIALYSIS; PREVALENCE; PRIORITY JOURNAL; SCREENING TEST;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CATHETERS, INDWELLING; DRUG RESISTANCE, BACTERIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METHICILLIN RESISTANCE; MIDDLE AGED; MUPIROCIN; PERITONEAL DIALYSIS; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TIME FACTORS;

EID: 19944428900     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh494     Document Type: Article

References (21)

1. Davies SJ, Ogg CS, Cameron JS, Poston S, Noble WC. Staphylococcus aureus nasal carriage, exit-site infection and catheter loss in patients treated with continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int 1989; 9: 61-64
2. Wanten GJ, van Oost P, Schneeberger PM, Koolen MI. Nasal carriage and peritonitis by Staphylococcus aureus in patients on continuous ambulatory peritoneal dialysis: a prospective study. Perit Dial Int 1996; 16: 352-356
3. Amato D, de Jesus Ventura M, Miranda G et al. Staphylococcal peritonitis in continuous ambulatory peritoneal dialysis: colonization with identical strains at exit site, nose, and hands. Am J Kidney Dis 2001; 37: 43-48
4. Laupland KB, Conly JM. Treatment of Staphylococcus aureus colonization and prophylaxis for infection with topical intranasal mupirocin: an evidence-based review. Clin Infect Dis 2003; 37: 933-938
5. Tacconelli E, Carmeli Y, Aizer A, Ferreira G, Foreman MG, D'Agata EM. Mupirocin prophylaxis to prevent Staphylococcus aureus infection in patients undergoing dialysis: a meta-analysis. Clin Infect Dis 2003; 37: 1629-1638
6. Crabtree JH, Hadnott LL, Burchette RJ, Siddiqi RA. Outcome and clinical implications of a surveillance and treatment program for Staphylococcus aureus nasal carriage in peritoneal dialysis patients. Adv Perit Dial 2000; 16: 271-275
7. Perez-Fontan M, Garcia-Falcon T, Rosales M et al. Treatment of Staphylococcus aureus nasal carriers in continuous ambulatory peritoneal dialysis with mupirocin: long-term results. Am J Kidney Dis 1993; 22: 708-712
8. Thodis E, Passadakis P, Panagoutsos S, Bacharaki D, Euthimiadou A, Vargemezis V. The effectiveness of mupirocin preventing Staphylococcus aureus in catheter-related infections in peritoneal dialysis. Adv Perit Dial 2000; 16: 257-261
9. Thodis E, Bhaskaran S, Pasadakis P, Bargman JM, Vas SI, Oreopoulos DG. Decrease in Staphylococcus aureus exit-site infections and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter exit site. Perit Dial Int 1998; 18: 261-270
10. Casey M, Taylor J, Clinard P et al. Application of mupirocin cream at the catheter exit site reduces exit-site infections and peritonitis in peritoneal dialysis patients. Perit Dial Int 2000; 20: 566-568
11. Vas SI, Conly J, Bargman JM, Oreopoulos DG. Resistance to mupirocin: no indication of it to date while using mupirocin ointment for prevention of Staphylococcus aureus exit-site infections in peritoneal dialysis patients. Perit Dial Int 1999; 19: 313-314
12. Annigeri R, Conly J, Vas S et al. Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection. Perit Dial Int 2001; 21: 554-559
13. Perez-Fontan M, Rosales M, Rodriguez-Carmona A, Falcon TG, Valdes F. Mupirocin resistance after long-term use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis. Am J Kidney Dis 2002; 39: 337-341
14. Conly JM, Vas S. Increasing mupirocin resistance of Staphylococcus aureus in CAPD, should it be continue to be used as prophylaxis. Perit Dial Int 2002; 22: 649-652
15. Perez Fontan M, Rosales M, Rodriguez Carmona A et al. Treatment of Staphylococcus aureus nasal carriers in CAPD with mupirocin. Adv Perit Dial 1992; 8: 242-245
16. Turner K, Uttley L, Scrimgeour A, McKewan A, Gokal R. Natural history of Staphylococcus aureus nasal carriage and its relation to exit site infection. Perit Dial Int 1998; 18: 271-273
17. Wanten GJ, Schneeberger PM, Bevers A, van Ginneken E, Koolen MI. Optimizing screening procedures for Staphylococcus aureus nasal carriage in patients on haemodialysis. Nephrol Dial Transplant 1998; 13: 1256-1258
18. Cavdar C, Zeybel M, Atay T et al. The effects of once or three times weekly mupirocin application on mupirocin resistance in CAPD patients: first six months experience [abstract]. Perit Dial Int 2004; 24: S33
19. Cookson BD. The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice. J Antimicrob Chemother 1998; 41: 11-18
20. Walker ES, Vasquez JE, Dula R, Bullock H, Sarubbi FA. Mupirocin-resistant, methicillin-resistant Staphylococcus aureus: does mupirocin remain effective? Infect Control Hosp Epidemiol 2003; 24: 342-346
21. Semret M, Miller MA. Topical mupirocin for eradication of MRSA colonization with mupirocin-resistant strains. Infect Control Hosp Epidemiol 2001; 22: 578-580